Sort   by:  
 Page size 
UnknownLung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial
Highlights • We report on the credentialing experience of a Phase III trial of SBRT versus hypofractionated RT for stage I lung cancer.• Elements included a site survey, phantom test, and a standardized case for a peripheral and central tumour.• Approximately 1/3 of plans required resubmission due t...
S-EPMC9579727 | biostudies-literature
UnknownHematologic complications with age in Shwachman-Diamond syndrome.
Shwachman-Diamond syndrome (SDS) is an inherited bone marrow failure syndrome with leukemia predisposition. An understanding of the hematologic complications of SDS with age could guide clinical management, but data are limited for this rare disease. We conducted a cohort study of 153 subjects from ...
S-EPMC8753194 | biostudies-literature
UnknownSingle-Dose Treatment with Rapamycin Preserves Post-Ischemic Cardiac Function through Attenuation of Fibrosis and Inflammation in Diabetic Rabbit.
Robust activation of mTOR (mammalian target of rapamycin) signaling in diabetes exacerbates myocardial injury following lethal ischemia due to accelerated cardiomyocyte death with cardiac remodeling and inflammatory responses. We examined the effect of rapamycin (RAPA, mTOR inhibitor) on cardiac rem...
S-EPMC10218967 | biostudies-literature
UnknownMeta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus.

Introduction

Systemic lupus erythematosus (SLE) is a heterogeneous disease with a diverse spectrum of clinical symptoms, ranging from skin rash to end-organ damage. 22q11.21 has been identified as a susceptibility region for several autoimmune diseases, including SLE. However, detailed infor...
S-EPMC4404227 | biostudies-literature
UnknownImpact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure.

Background and aims

Acute-on-chronic liver failure (ACLF) is considered a main prognostic event in patients with chronic liver disease (CLD). We analyzed the 28-day and 90-day mortality in ACLF patients with or without underlying cirrhosis enrolled in the ACLF Research Consortium (AARC) data...
S-EPMC8844167 | biostudies-literature
UnknownManagement of Coronary Disease in Patients with Advanced Kidney Disease.

Background

Clinical trials that have assessed the effect of revascularization in patients with stable coronary disease have routinely excluded those with advanced chronic kidney disease.

Methods

We randomly assigned 777 patients with advanced kidney disease and moderate or severe isch...
S-EPMC7274537 | biostudies-literature
UnknownSerum Proteomic Profile Based on the TGF-β Pathway Stratifies Risk of Hepatocellular Carcinoma.

Background

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths, primarily due to late-stage diagnosis. In this multicenter study, our goal is to identify functional biomarkers that stratify the risk of HCC in patients with cirrhosis (CP) for early diagnosis.
S-EPMC12416123 | biostudies-literature
UnknownPre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).

Background and aims

COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or with...
S-EPMC7334898 | biostudies-literature
UnknownPreclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma.

Background

Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric brain tumor affecting over 300 children annually in the United States. Chimeric antigen receptor (CAR) T cells are a targeted immune effector cell therapy with substantial clinical benefit against hematologic cancers. Ag...
S-EPMC12424946 | biostudies-literature
TranscriptomicsAntiangiogenic Antithrombin
Confluent passage-2 HUVECs in Falcon T12.5 flasks grown in the presence or absence of VEGF-165 (10ng/mL) (R&D systems) were treated with human native, cleaved or latent antithrombins (20 5g/mL) for 24 hours in 3 mL M-199 with 2% heat-inactivated FBS and antibiotics. Following this treatment, tot...
ORGANISM(S): Homo sapiens 
2005-12-30 | E-GEOD-3956 | biostudies-arrayexpress
Sort   by:  
 Page size